Cardiac Remodeling

Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients

By MedXY 02/09/2026

A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.

Cardiology Internal Medicine news

Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial

By MedXY 01/17/2026

The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiology news

Genetic Susceptibility and Elite Rowing: The Dual Drivers of Atrial Fibrillation Risk in Former Athletes

By MedXY 01/06/2026

A landmark study reveals that former world-class rowers face a seven-fold higher risk of atrial fibrillation compared to the general population, driven by a combination of intensive cardiac remodeling and a strong polygenic predisposition.

Cardiology Family Medicine & Nutrition news

Higher-Quality Carbohydrates and Fibre-Rich Foods Associate with Better Left Ventricular Structure and Function: Insights from CARDIA

By MedXY 11/28/2025

In the CARDIA cohort, higher carbohydrate quality (lower carbohydrate:fibre ratio) and greater intake of fibre-rich foods were associated with more favorable left ventricular structure and function measured 25–30 years after baseline diet assessment.

Cardiology Nephrology news

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

By MedXY 10/30/2025

Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.

Cardiology Diabetes & Endocrinology Specialties

Untangling Adiposity and Insulin Resistance in HFpEF: Clarifying Their Distinct Impact on Cardiac Function

By MedXY 08/22/2025

This study reveals that excess adiposity, rather than insulin resistance or diabetes, predominantly drives left heart abnormalities and elevated pulmonary pressures in HFpEF, highlighting the need for targeted cardiometabolic therapies beyond glucose control.

Cardiology news Specialties

Aficamten in Obstructive Hypertrophic Cardiomyopathy: Durable 48-Week Benefits and Insights on Combination Therapy

By MedXY 08/17/2025

Aficamten shows sustained obstruction relief, symptom improvement, and favorable cardiac remodeling over 48 weeks in obstructive hypertrophic cardiomyopathy, with safe discontinuation of disopyramide possible.